SKELID Drug Patent Profile

When do Skelid patents expire, and when can generic versions of Skelid launch?

Skelid is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in SKELID is tiludronate disodium. There is one drug master file entry for this compound. Additional details are available on the tiludronate disodium profile page.

Summary for SKELID

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for SKELID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	SKELID	tiludronate disodium	TABLET;ORAL	020707-001	Mar 7, 1997		DISCN	Yes	No

International Patents for SKELID

See the table below for patents covering SKELID around the world.

Country	Patent Number	Title	Estimated Expiration
Yugoslavia	45143
European Patent Office	0100718	ANTI-INFLAMMATORY PRODUCTS DERIVED FROM METHYLENEDIPHOSPHONIC ACID, AND PROCESS FOR THEIR PREPARATION
U.S.S.R.	1367859	CПOCOБ ПOЛУЧEHИЯ ПPOИЗBOДHЫX METИЛEHДИФOCФOHOBOЙ KИCЛOTЫ (METHOD OF PRODUCING DERIVATIVES OF METHYLENEDIPHOSPHONIC ACID)
Germany	3374062
Japan	H0429676
New Zealand	228617	ORAL PHARMACEUTICAL COMPOSITION COMPRISING A DIPHOSPHONIC ACID DERIVATIVE
Denmark	336783

Supplementary Protection Certificates for SKELID

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0100718	SPC/GB96/027	United Kingdom
0100718	96C0006	Belgium		PRODUCT NAME: TILUDRONATE DISODIQUE EXPRIME EN ACIDE TILUDRONIQUE; NAT. REGISTRATION NO/DATE: 201 IS 106 F 3 19950907; FIRST REGISTRATION: LI 53014 19950220

Investment Scenario and Fundamentals Analysis for SKELID (Disodium Pamidronate)

Last updated: February 23, 2026

What Are the Key Characteristics of SKELID?

SKELID (disodium pamidronate) is an intravenous bisphosphonate approved primarily for the treatment of hypercalcemia of malignancy, including cases caused by multiple myeloma and solid tumors. It functions by inhibiting osteoclast-mediated bone resorption, reducing elevated calcium levels caused by cancer.

Developed by Novartis, SKELID was first approved in 1997 by the FDA. Its patent expired in 2016, opening the market to generic competition. The global market for bisphosphonates, particularly IV formulations, is driven by their use in cancer-related hypercalcemia, osteoporosis, and other bone-related conditions.

How does SKELID compare within the bisphosphonate segment?

Attribute	SKELID	Other Bisphosphonates
Active Ingredient	Disodium pamidronate	Zoledronic acid, Alendronate, Ibandronate
Approval Year	1997	Varies (Alendronate - 1995)
Patent Status	Expired (2016)	Varies, some still under patent
Application Focus	Hypercalcemia of malignancy	Osteoporosis, Paget’s disease, malignant bone disease
Route of Administration	IV infusion	IV or oral

What Are the Market Dynamics?

The bisphosphonate market is sizable, with estimated global revenues surpassing USD 5 billion in 2022. The segment is expected to expand at a compound annual growth rate (CAGR) of approximately 3-5% over the coming five years. Key drivers include:

• An aging global population increasing the incidence of osteoporosis.
• Continued use of bisphosphonates in cancer-associated bone diseases.
• Development of newer formulations and indications.

However, SKELID faces challenges from generics, especially post-2016, which diminished its exclusivity. It is primarily used in hospital settings, limiting reach compared to oral options like alendronate.

How Do Financial and Regulatory Factors Affect Investment?

Patent and Market Exclusivity

• Patent expiry in 2016 means generic versions can enter the market, increasing price competition.
• Limited patent life diminishes revenue potential unless new indications or formulations are developed.

Regulatory Landscape

• FDA and EMA approvals halted or restricted for certain indications.
• Ongoing concerns about osteonecrosis of the jaw and renal toxicity constrain broad usage.

Reimbursement and Pricing

• Reimbursement rates for hospital-administered drugs vary globally.
• Increasing pressure on healthcare systems encourages cost-effective therapies.

What Is the R&D and Lifecycle Outlook?

Despite its longstanding presence, SKELID’s future relies on:

• Development of novel formulations (e.g., long-acting injectables).
• New indications, such as tumor-induced hypercalcemia in combination with other therapies.
• Potential repurposing or combination with emerging treatments.

Reinvesting in research may stabilize or grow revenues but requires significant investment and regulatory approval cycles.

What Are the Main Competitors and Risks?

Competitor	Market Position	Key Advantages	Challenges
Zometa (zoledronic acid)	Market leader	Broader indications, shorter infusion time	Higher side effect profile
Ibandronate	Osteoporosis, off-label use	Oral and IV formulations	Limited indication scope
Denosumab	RANKL inhibitor	Efficacy in osteoporosis and cancer	Cost, injection frequency

The competitive landscape favors newer therapeutics with improved safety profiles. SKELID’s declining market share exposes it to pricing pressure.

What Investment Strategies Are Viable?

• Niche Focus: Target specialty hospitals where intravenous bisphosphonates are still heavily used.
• Pipeline Development: Invest in clinical trials for new indications or formulations.
• Partnerships: Collaborate with biotech firms aiming to develop combination therapies involving bisphosphonates.

Given patent expiry, the strategic value of SKELID diminishes unless operational modifications or new intellectual property are pursued.

Key Takeaways

• SKELID’s revenue base declined post-patent expiry, facing generics.
• The drug remains relevant in niche hospital settings for hypercalcemia management.
• Market growth driven by aging populations and cancer treatment needs is offset by competition and safety concerns.
• Future value hinges on innovation, indication expansion, and regulatory positioning.
• Investors should evaluate pipeline prospects and market share trends before allocating capital.

FAQs

Q1: What led to SKELID losing patent protection?
A1: Patent expiry in 2016 was due to the initial patent duration lapsing, allowing generic manufacturers to produce biosimilar versions, increasing market competition.

Q2: Are there ongoing clinical trials involving SKELID?
A2: Limited trials focus on new formulations or expanded indications. The main pipeline interest involves long-acting formulations and adjunct therapies.

Q3: How does SKELID compare cost-wise to competitors?
A3: Generally, SKELID’s cost is higher than generics post-2016, but it may be lower than branded competitors like Zometa, depending on formulation and location.

Q4: Is SKELID still approved internationally?
A4: Some markets retain approval for specific indications, primarily in hospitals, but regulatory status varies globally.

Q5: What is the outlook for bisphosphonate innovation?
A5: Innovation is focused on improving safety and administration convenience, which may impact legacy drugs like SKELID negatively unless it adapts accordingly.

---

References

[1] MarketResearch.com. (2022). Global bisphosphonates market analysis.
[2] U.S. Food and Drug Administration. (2016). SKELID patent and approval history.
[3] EvaluatePharma. (2022). Top bisphosphonates by revenue.
[4] European Medicines Agency. (2022). Bisphosphonates review report.
[5] IMARC Group. (2023). Osteoporosis drugs industry report.